Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by BeiGene, Ltd.
< Previous
1
2
3
Next >
BeiGene Receives Positive CHMP Opinion for TEVIMBRA® as a First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
March 31, 2025
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy
March 04, 2025
From
BeiGene, Ltd.
Via
Business Wire
Tickers
ONC
BeiGene Announces Fourth Quarter and Full Year 2024 Financial Results and Business Updates
February 27, 2025
From
BeiGene, Ltd.
Via
Business Wire
Tickers
ONC
BeiGene to Announce Fourth Quarter and Full Year 2024 Financial Results on February 27
February 13, 2025
From
BeiGene, Ltd.
Via
Business Wire
Tickers
ONC
TEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
December 27, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
December 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
December 12, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets
December 09, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene and CLL Society Partner to Advance Test Before Treat™ Campaign, Promoting Biomarker Testing to Improve Patient Outcomes in CLL
December 04, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Host Investor Webcast Highlighting Key Data from ASH and the San Antonio Breast Cancer Symposium on December 16, 2024
December 02, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
European Commission Approves BeiGene’s TEVIMBRA for First-Line Treatment of Advanced/Metastatic Esophageal Squamous Cell Carcinoma and Gastric or Gastroesophageal Junction Cancer
November 27, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at Upcoming Investor Conferences
November 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Settlement of Litigation Against Generic Filer of BRUKINSA
November 19, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Unveils Proposed Name Change to BeOne Medicines, Reaffirming Its Mission to Unite Global Community Against Cancer
November 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Third Quarter 2024 Financial Results and Corporate Updates
November 12, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Jefferies London Healthcare Conference
November 06, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
November 05, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Mourns Death of Beloved Board Member Donald Glazer
October 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Receives Positive CHMP Opinions for TEVIMBRA® as a First-Line Treatment for Advanced/Metastatic Gastric or Gastroesophageal Junction Cancer and Esophageal Squamous Cell Carcinoma
October 21, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Highlights Waldenström’s Macroglobulinemia Innovation at IWWM 2024
October 16, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers
September 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors
September 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Updates to Commercial Leadership Team
September 09, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
August 28, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene’s BGB-16673 Receives U.S. FDA Fast Track Designation for CLL/SLL
August 26, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Opens Flagship U.S. Biologics Manufacturing and Clinical R&D Facility, Continues Global Expansion to Deliver Medicines to More Patients Around the World
July 23, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene Announces Appointment of Aaron Rosenberg as Chief Financial Officer
July 18, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present New Data from SEQUOIA Study Evaluating BRUKINSA® plus Venetoclax in High-Risk First-Line CLL/SLL at EHA2024
June 14, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BeiGene to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
June 04, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
BRUKINSA® Data at ASCO Underscore Differentiated Clinical Profile for Treatment of CLL and SLL
May 24, 2024
From
BeiGene, Ltd.
Via
Business Wire
Tickers
BGNE
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.